Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease
Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the effect of 3 doses of SSR180711C on
cognitive performance in patients with mild Alzheimer's Disease (AD). Other objectives are to
assess the safety/tolerability of SSR180711C in patients with mild AD.